Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,561 | 174 | 1,386 |
| Samples | 168 | 30 | 137 |
| Peptides | 168 | 27 | 144 |
Function
IL15RA · Interleukin 15 receptor subunit alpha
This gene encodes a cytokine receptor that specifically binds interleukin 15 (IL15) with high affinity. The receptors of IL15 and IL2 share two subunits, IL2R beta and IL2R gamma. This forms the basis of many overlapping biological activities of IL15 and IL2. The protein encoded by this gene is structurally related to IL2R alpha, an additional IL2-specific alpha subunit necessary for high affinity IL2 binding. Unlike IL2RA, IL15RA is capable of binding IL15 with high affinity independent of other subunits, which suggests distinct roles between IL15 and IL2. This receptor is reported to enhance cell proliferation and expression of apoptosis inhibitor BCL2L1/BCL2-XL and BCL2. Multiple alternatively spliced transcript variants of this gene have been reported.[provided by RefSeq, Apr 2010].
Isoforms & Proteins
12 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000379977 | Q13261 | 165 | 109 |
| ENST00000397248 | A0A0A0MS77* | 154 | 105 |
| ENST00000525219 | Q13261-10 | 141 | 96 |
| ENST00000528354 | Q13261-3 | 141 | 95 |
| ENST00000397251 | K9N1J3* | 134 | 87 |
| ENST00000620345 | K9N163* | 134 | 87 |
| ENST00000622442 | K9N2Q6* | 134 | 87 |
| ENST00000397255 | Q13261-4 | 133 | 86 |
| ENST00000620865 | K9N2S2* | 132 | 86 |
| ENST00000530685 | Q13261-5 | 123 | 79 |
| ENST00000397250 | Q13261-8 | 94 | 63 |
| ENST00000379971 | Q13261-9 | 76 | 47 |
Gene Properties
Recurrent Mutations
All 109 amino-acid changes on canonical ENST00000379977 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in IL15RA · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in IL15RA – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chordoma | 2/7 29% | 0/13 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 6/133 5% |
| Melanoma | 0/210 0% | 27/1899 1% |
| Chondrosarcoma | 0/14 0% | 1/75 1% |
| Cervical Carcinoma | 2/35 6% | 3/422 1% |
| Germ Cell Tumour | 2/25 8% | 0/169 0% |
| Endometrial Carcinoma | 3/42 7% | 2/612 0% |
| Non-Cancerous | 0/104 0% | 7/830 1% |
| Ewings Sarcoma | 1/63 2% | 1/262 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 4/752 1% |
| Colorectal Carcinoma | 5/143 4% | 13/3239 0% |
| Bladder Carcinoma | 1/58 2% | 4/956 0% |
| Gastric Carcinoma | 0/74 0% | 9/1809 0% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Other Solid Cancers | 0/94 0% | 7/1515 0% |
| Neuroendocrine Tumour | 2/154 1% | 1/577 0% |
| Glioma | 0/52 0% | 9/2127 0% |
| Non-Small Cell Lung Carcinoma | 1/304 0% | 6/1390 0% |
| Other Sarcomas | 2/69 3% | 1/699 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 5/1592 0% |
| Plasma Cell Myeloma | 1/44 2% | 0/305 0% |
| Esophageal Carcinoma | 2/23 9% | 0/769 0% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 5/2550 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| Breast Carcinoma | 2/144 1% | 5/3264 0% |
| Kidney Carcinoma | 0/85 0% | 4/1862 0% |
| Pancreatic Carcinoma | 0/89 0% | 3/1611 0% |
| Hepatocellular Carcinoma | 1/46 2% | 3/2210 0% |
| Neuroblastoma | 0/87 0% | 2/1331 0% |
| Other Blood Cancers | 0/61 0% | 4/2725 0% |
Mutation Distribution
Where IL15RA is mutated · all tissues, split by cell line vs tissue
How many mutations in IL15RA were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,561 mutations in IL15RA
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|